An acid-stable insulin-like growth factor (IGF)-binding protein from pig serum inhibits binding of IGF-I and IGF-II to vascular endothelial cells
- 1 February 1989
- journal article
- research article
- Published by Bioscientifica in Journal of Endocrinology
- Vol. 120 (2) , 231-236
- https://doi.org/10.1677/joe.0.1200231
Abstract
The effects of a porcine insulin-like growth factor (IGF)-binding protein on binding of IGF-I and IGF-II to porcine aortic endothelial cells (PAEC) were determined. Binding of 125I-labelled IGF-I and -II to IGF receptors was inhibited by IGF-binding protein. IGF-binding protein inhibited binding of IGF-I and -II in a dose-dependent manner with half-maximal inhibition occurring at 5·43 and 108 μg/l respectively. A125I-labelled IGF-I–IGF-binding protein complex, formed by incubating 125I-labelled IGF-I with IGF-binding protein overnight at 4 °C, did not effectively bind to endothelial IGF receptors. Addition of IGF-binding protein to PAEC previously incubated with IGF-I caused a marked dissociation of bound IGF-I (47% dissociation within 12 h). These results indicate that the acid-stable IGF-binding protein which appears to be a part of the 150 kDa GH-dependent binding protein, blocks binding of IGF-I and -II by the IGF receptors and appears to exhibit a higher affinity for IGF-I than the endothelial type-I IGF receptor. The ramifications of this latter point with respect to transfer of circulating IGFs (bound to their IGF-binding proteins) across the vascular endothelium are not clear. Journal of Endocrinology (1989) 120, 231–236This publication has 22 references indexed in Scilit:
- Affinity-labeled plasma somatomedin-C/insulinlike growth factor I binding proteins. Evidence of growth hormone dependence and subunit structure.Journal of Clinical Investigation, 1985
- Immunoassay of a Somatomedin-Binding Protein from Human Amniotic Fluid: Levels in Fetal, Neonatal, and Adult Sera*Journal of Clinical Endocrinology & Metabolism, 1984
- Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action.Proceedings of the National Academy of Sciences, 1984
- Effect of in Vitro Action of Serum Proteases or Exposure to Acid on Measurable Immunoreactive Somatomedin-C in Serum*Journal of Clinical Endocrinology & Metabolism, 1983
- Inhibition of biological activity of multiplication-stimulating activity by binding to its carrier protein.Proceedings of the National Academy of Sciences, 1980
- The Somatomedin C Binding Protein: Evidence for a Heterologous Subunit Structure*Journal of Clinical Endocrinology & Metabolism, 1980
- Inhibition of the Action of Nonsuppressible Insulin-Like Activity on Isolated Rat Fat Cells by Binding to its Carrier ProteinJournal of Clinical Investigation, 1979
- PARTIAL PURIFICATION AND CHARACTERIZATION OF A BINDING PROTEIN FOR INSULIN-LIKE ACTIVITY (ILAs) IN HUMAN AMNIOTIC FLUID: A POSSIBLE INHIBITOR OF INSULIN-LIKE ACTIVITYActa Endocrinologica, 1979
- NSILA-carrier protein abolishes the action of nonsuppressible insulin-like activity (NSILA-S) on perfused rat heartDiabetologia, 1978
- Demonstration of Specific Plasma Protein Binding Sites For SomatomedinJournal of Clinical Endocrinology & Metabolism, 1977